Anzeige
Meldung des Tages: Diese Kupfer-News kam leise – KI, Energie, Defense: Warum jetzt plötzlich alles an Kupfer hängt

Compugen News

Aktie
WKN:  553001 ISIN:  IL0010852080 US-Symbol:  CGEN Branche:  Biotechnologie Land:  Israel
1,792 €
+0,004 €
+0,22%
26.03.26
Depot/Watchlist
Marktkapitalisierung *
122,33 Mio. €
Streubesitz
84,32%
KGV
-
Index-Zuordnung
-

Compugen News

26.03.25 - PR Newswire
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 PR Newswire
04.03.25 - PR Newswire
/C O R R E C T I O N -- Compugen Ltd./
/C O R R E C T I O N -- Compugen Ltd./ PR Newswire
03.03.25 - PR Newswire
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference PR Newswire
26.02.25 - PR Newswire
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology PR Newswire
18.02.25 - PR Newswire
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 PR Newswire
04.02.25 - PR Newswire
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference PR Newswire
08.01.25 - PR Newswire
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors PR ...
27.11.24 - PR Newswire
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-​TIGIT) with anti-PD-1 and anti-​PVRIG ...
12.11.24 - PR Newswire
Compugen Reports Third Quarter 2024 Results
Compugen Reports Third Quarter 2024 Results PR Newswire
11.11.24 - PR Newswire
Compugen to Participate in Stifel 2024 Healthcare Conference
Compugen to Participate in Stifel 2024 Healthcare Conference PR Newswire
05.11.24 - PR Newswire
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Compugen to Present Anti-​Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 ...
29.10.24 - PR Newswire
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 PR Newswire
07.10.24 - PR Newswire
Compugen to Present New Clinical Data at SITC 2024
Compugen to Present New Clinical Data at SITC 2024 PR Newswire
09.09.24 - PR Newswire
Compugen to Present at Single Cell Genomics 2024 Conference
Compugen to Present at Single Cell Genomics 2024 Conference PR Newswire
29.08.24 - PR Newswire
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire
06.08.24 - PR Newswire
Compugen Reports Second Quarter 2024 Results
Compugen Reports Second Quarter 2024 Results PR Newswire
29.07.24 - PR Newswire
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire
23.07.24 - PR Newswire
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire
17.06.24 - PR Newswire
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire
30.05.24 - PR Newswire
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire

Newssuche

Videos

newspaper
23.03.26 +6,96%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »